Is PRFX or RGC more undervalued in 2026?

CirclFi compares PRF Technologies Ltd. (PRFX) and Regencell Bioscience Holdings L (RGC) using 13 institutional-grade valuation models. PRFX has a Quality of Company score of 4.4/10 while RGC scores 4.6/10.

Which is a better buy — PRFX or RGC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PRFX and RGC valuations compare?

PRFX at $1.37 and RGC at $24.11 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PRFX vs RGC Valuation Comparison 2026 — Intrinsic Value Analysis

PRFX

Drug Manufacturers - Specialty & Generic

PRF Technologies Ltd.

Quality

4.4

out of 10

Value Trap

LOW

Price

$1.37

Last close

Models

8/13

Active

RGC

Drug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings L

Quality

4.6

out of 10

Value Trap

SAFE

Price

$24.11

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	PRFX Fair Value	PRFX Upside	RGC Fair Value	RGC Upside
Bayesian DCF	Intrinsic	$2.07	+50.8%	$8.05	-66.6%
Earnings Power Value	Intrinsic	—	—	$11.09	-59.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$2.26	+65.3%	$0.01	-100.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PRFX vs RGC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PRFX vs RGC — Which Stock Is More Undervalued?

RGC scores higher with a 4.6/10 quality rating vs PRFX's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PRF Technologies Ltd. (PRFX) and Regencell Bioscience Holdings L (RGC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PRFX currently trades at $1.37 with a QOC of 4.4/10, while RGC trades at $24.11 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).